[ad_1]
HYDERABAD: Praxair India Private Limited, which is a part of global industrial gases and engineering giant Linde, said it has commenced commercial production at its air separation unit (ASU) at Patancheru in Hyderabad.
The facility will be producing 250 tonnes per day of gases, including liquid medical oxygen, nitrogen and argon to cater to the requirements of healthcare, pharma and other industrial sectors of the region.
The construction of the ASU, which commenced in April 2022 after Linde received official approval from the Telangana government, was completed within a timeframe of 18 months, it said.
“The new Hyderabad ASU provides us with a manufacturing base in the key market of Telangana and will reduce dependency on supply from other states,” said RC Kaushik, head of sales, healthcare & AT, Linde-India.
“With the start of this plant we will be well placed to match the growth expectations in this region and also cater to our healthcare customers and the expanding pharma sector in the state more effectively and efficiently.”
“We were focused on completing the construction within the stipulated 18-month timeframe despite challenges along the way which impacted the import of critical equipment,” said Anirudh Gharote, executive director, Praxair India Pvt Ltd.
The facility will be producing 250 tonnes per day of gases, including liquid medical oxygen, nitrogen and argon to cater to the requirements of healthcare, pharma and other industrial sectors of the region.
The construction of the ASU, which commenced in April 2022 after Linde received official approval from the Telangana government, was completed within a timeframe of 18 months, it said.
“The new Hyderabad ASU provides us with a manufacturing base in the key market of Telangana and will reduce dependency on supply from other states,” said RC Kaushik, head of sales, healthcare & AT, Linde-India.
“With the start of this plant we will be well placed to match the growth expectations in this region and also cater to our healthcare customers and the expanding pharma sector in the state more effectively and efficiently.”
“We were focused on completing the construction within the stipulated 18-month timeframe despite challenges along the way which impacted the import of critical equipment,” said Anirudh Gharote, executive director, Praxair India Pvt Ltd.
[ad_2]
Source link
More Stories
India’S Growth Forecast: S&P ups India’s FY’24 growth forecast to 6.4% on robust domestic momentum
India to remain fastest-growing major economy, but demand uneven: Poll
Jack Ma: Jack Ma gets back into business with ‘Ma’s Kitchen Food’